Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...